.png)
SummaryItaly publishes its medicine prices openly, under a licence that permits commercial reuse, and one of the two main lists carries the manufacturer price directly. That combination is rare in Europe. The catch is not legal and not structural, it is timeliness: the headline lists can sit unchanged for months, and a product that sells price currency has to know which branch of the Italian data is actually fresh.
The national medicines agency maintains two price lists that matter for cross-border work.
Classe A is the reimbursed outpatient list. It carries a retail price including VAT.
Classe H is the hospital list. It carries the ex-factory price directly, per pack, with the national code. For anyone building a European price dataset, that makes Italy one of the few countries where a manufacturer level figure arrives without a derivation.
| Property | Classe A | Classe H |
|---|---|---|
| Price level | Retail including VAT | Ex-factory, published directly |
| Format | CSV and ODS | CSV and ODS |
| Pack code | AIC | AIC |
| Licence | CC BY 4.0, commercial use explicitly permitted | CC BY 4.0 |
| Derivation needed | VAT plus a combined margin | None |
Both files were retrieved on 5 September 2026, the Classe A file at 1,512,604 bytes and the Classe H file at 412,538 bytes.
Two operations take the Italian retail price down to the manufacturer level.
Remove VAT at 10 percent. Italy applies a reduced rate to medicines.
Remove a combined margin of 33.35 percent, covering pharmacy and distribution together. The legal basis is Decreto Legge 78/2010, chapter III, article 11 paragraph 6.
One warning belongs with that figure. The combined rate of 33.35 percent is not the sum of the individual margins that appear in overview tables, 30.35 percent for the pharmacy and 3.00 percent for distribution. It is a value in its own right, set in law, and it has to be treated as such rather than reconstructed from the components. Anyone who builds the Italian calculation by adding the two published components will produce a number that is close to the right answer and never equal to it.
On 5 September 2026 both main lists still stood at the state of 30 April 2026. Four months old. For a comparison of price levels between countries that is tolerable. For a product that promises current prices it is not.
The fresher branch is the transparency lists, which appear monthly. For any pipeline that sells currency of data, that branch has to be the primary source and the headline lists become the reference for structure and completeness. This is a case where the technically obvious source and the operationally correct source are not the same file, and the decision has to be made explicitly.
We do not link the Italian bulk files here because the CSV endpoint returned HTTP 502 on our check on 14 September 2026. The lists are reachable through the agency's open data section, and any pipeline should verify the endpoint on every run rather than assuming a stable URL.
Italy identifies packs with the AIC code, which is pack specific and carries the join. There is no GTIN in the price files.
The pack description is present and largely machine readable, but it is not a clean number. Our own assessment puts the Italian mapping problem at the low end: the code does the work, and the pack size can be parsed from the description and validated against the marketing authorisation database.
The practical consequence is the same as in France. Join on the national code, parse the description only to check the result, and never let a parsed pack size override a code based match.
Three things, and they decide whether a commercial data source is needed at all.
The useful conclusion for procurement teams: a commercial Italian data source is worth paying for because of the attributes, not because of the price. The price itself is public, and for the hospital segment it is published at manufacturer level.
The distance between the two Italian lists is the distribution system itself. A Classe H price is what the manufacturer receives. A Classe A price is that same figure plus the combined trade margin plus tax. Reading the two lists side by side is therefore a useful exercise for anyone who wants to see, on real data, how much of a published European price is the medicine and how much is the chain that moves it.
It also shows why a single national average across both lists is meaningless. The two figures sit at different points of the chain, and averaging them measures the composition of the assortment rather than the level of prices.
Every derived manufacturer price from Classe A should travel with four labels: the source list and its date, the VAT rate applied, the legal basis of the margin, and the fact that the result is derived rather than published. The last one is the label most often dropped, and it is the one that turns a defensible calculation into a claim that cannot be checked.
Where a pack appears in both lists, the direct Classe H figure wins. A published number always beats a derived one, even when the derivation is legally exact, because the published number carries no assumption about which rule version was in force.
Two reasons, and they have nothing to do with the size of the Italian market.
First, Classe H is one of very few European sources where the ex-factory price per pack is official, direct and freely licensed. That makes Italy a natural anchor when testing a European normalisation pipeline: you can compare a derived manufacturer price in another country against a directly published one here and see how far a derivation drifts.
Second, Italy is the clearest available evidence on what pharmaceutical reference data is worth commercially. Public procurement records there show a licensing model built on the type of use rather than the volume of data: roughly 1,140 euro net per year for a daily full XML package used inside one organisation, roughly 5,000 to 7,000 euro per year for each integration into a third party application, and 600 euro per year per pharmacy in the mass market. The supplier behind those figures turns over around 11.6 million euro with about 45 employees.
For anyone building a European price product, that is the more interesting finding: the price differentiation follows the type of use, not the amount of data delivered.
What does the manufacturer receive for a hospital product? Directly, from the hospital list, per pack, with the national code.
How large is the trade margin on an outpatient product? Exactly, because the rate is set in law and the retail price is published.
Is a European comparison at manufacturer level plausible? Italy is the country where you can test that question against a published figure instead of an assumption.
What Italian data does not answer is anything about the non-reimbursed segment, or about what a hospital actually paid after a tender. Both are outside the published universe, and no amount of processing recovers them.
Italy gives you an official manufacturer price for the hospital segment, a clean legal derivation for the outpatient segment, and a licence that allows commercial reuse. The work is not in the formula, it is in choosing the branch of the data that is actually current and in labelling what the lists leave out. Get those two right and Italy becomes one of the most reliable members of a European price basket.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus ex-factory price and VAT on medicines in Europe.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
